Table 1 Characteristics of patients
From: Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Patient # | Type of mts | No. of mts | Response |
|---|---|---|---|
999 | Visceral1 | > 3 | DP |
1025 | Visceral | < 3 | CR |
1080 | Visceral | > 3 | DP |
1081 | Visceral | < 3 | DP |
1083 | Visceral | > 3 | PR |
1095 | Visceral | < 3 | CR |
1125 | Visceral | > 3 | DP |
1126 | Visceral | < 3 | SD |
1102 | Non-visceral2 | > 3 | CR |
1103 | Non-visceral | < 3 | SD |
1110 | Non-visceral | < 3 | CR |
1121 | Non-visceral | > 3 | DP |
1123 | Non-visceral | < 3 | SD |
1124 | Non-visceral | < 3 | CR |
1019 | Mixed3 | > 3 | PR |
1020 | Mixed | > 3 | SD |
1021 | Mixed | > 3 | PR |
1026 | Mixed | > 3 | DP |
1082 | Mixed | > 3 | DP |
1104 | Mixed | > 3 | PR |
1105 | Mixed | > 3 | SD |
1116 | Mixed | > 3 | DP |
1270 | Visceral | < 3 | RC |
1276 | Mixed | > 3 | PR |
1279 | Non-visceral | < 3 | PR |
1280 | Visceral | > 3 | PD |